Benevolent News Hub

BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.

BenevolentAI is happy to announce it is sponsoring NeurIPS 2020. Join us to hear about data diversity and ML applied drug discovery, and to learn about careers in the field.

Last week, we brought together four of our exceptional colleagues for a panel discussion on careers in machine learning applied drug discovery. Here are some of our main takeaways:

Research published in Science Advances supports BenevolentAI’s AI-generated hypothesis from late January for baricitinib as a treatment for COVID-19.

BenevolentAI strengthens its Board with the appointment of AI pioneer Sir Nigel Shadbolt as Non-Executive Director.

We are thrilled to be welcoming Rob Quinn to the BenevolentAI team as our new Chief Finance Officer from January 2021

In this two-part blog, we propose ten practical approaches to improving data acquisition to encourage more inclusive research and improve the diversity of data used in drug discovery.

In this two-part blog, we propose ten practical approaches to improving data acquisition to encourage more inclusive research and improve the diversity of data used in drug discovery.

Additional data from the ACTT-2 randomised control trial shows reduced time to recovery and improved clinical outcomes for patients with COVID-19.

As a scientific advisor at BenevolentAI, Professor Russ Altman will help our scientists to further push the boundaries of machine learning applied drug discovery.